328 related articles for article (PubMed ID: 35563051)
81. Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia.
Pandzic T; Larsson J; He L; Kundu S; Ban K; Akhtar-Ali M; Hellström AR; Schuh A; Clifford R; Blakemore SJ; Strefford JC; Baumann T; Lopez-Guillermo A; Campo E; Ljungström V; Mansouri L; Rosenquist R; Sjöblom T; Hellström M
Clin Cancer Res; 2016 Dec; 22(24):6217-6227. PubMed ID: 26957556
[TBL] [Abstract][Full Text] [Related]
82. Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival.
Ferrajoli A; Ivan C; Ciccone M; Shimizu M; Kita Y; Ohtsuka M; D'Abundo L; Qiang J; Lerner S; Nouraee N; Rabe KG; Rassenti LZ; Van Roosbroeck K; Manning JT; Yuan Y; Zhang X; Shanafelt TD; Wierda WG; Sabbioni S; Tarrand JJ; Estrov Z; Radovich M; Liang H; Negrini M; Kipps TJ; Kay NE; Keating M; Calin GA
EBioMedicine; 2015 Jun; 2(6):572-82. PubMed ID: 26288818
[TBL] [Abstract][Full Text] [Related]
83. Pleiotropic drug resistance in B-cell chronic lymphocytic leukaemia--the role of Bcl-2 family dysregulation.
Pepper C; Thomas A; Hidalgo de Quintana J; Davies S; Hoy T; Bentley P
Leuk Res; 1999 Nov; 23(11):1007-14. PubMed ID: 10576505
[TBL] [Abstract][Full Text] [Related]
84. Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.
Ljungström V; Cortese D; Young E; Pandzic T; Mansouri L; Plevova K; Ntoufa S; Baliakas P; Clifford R; Sutton LA; Blakemore SJ; Stavroyianni N; Agathangelidis A; Rossi D; Höglund M; Kotaskova J; Juliusson G; Belessi C; Chiorazzi N; Panagiotidis P; Langerak AW; Smedby KE; Oscier D; Gaidano G; Schuh A; Davi F; Pott C; Strefford JC; Trentin L; Pospisilova S; Ghia P; Stamatopoulos K; Sjöblom T; Rosenquist R
Blood; 2016 Feb; 127(8):1007-16. PubMed ID: 26675346
[TBL] [Abstract][Full Text] [Related]
85. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.
Zenz T; Häbe S; Denzel T; Mohr J; Winkler D; Bühler A; Sarno A; Groner S; Mertens D; Busch R; Hallek M; Döhner H; Stilgenbauer S
Blood; 2009 Sep; 114(13):2589-97. PubMed ID: 19643983
[TBL] [Abstract][Full Text] [Related]
86. The pyrrolo-1,5-benzoxazepine, PBOX-15, enhances TRAIL‑induced apoptosis by upregulation of DR5 and downregulation of core cell survival proteins in acute lymphoblastic leukaemia cells.
Nathwani SM; Greene LM; Butini S; Campiani G; Williams DC; Samali A; Szegezdi E; Zisterer DM
Int J Oncol; 2016 Jul; 49(1):74-88. PubMed ID: 27176505
[TBL] [Abstract][Full Text] [Related]
87. The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology.
Boudny M; Trbusek M
Klin Onkol; 2020; 33(1):32-38. PubMed ID: 32075387
[TBL] [Abstract][Full Text] [Related]
88. Targeting the phosphatidylinositol 3-kinase/Akt/mechanistic target of rapamycin signaling pathway in B-lineage acute lymphoblastic leukemia: An update.
Simioni C; Martelli AM; Zauli G; Vitale M; McCubrey JA; Capitani S; Neri LM
J Cell Physiol; 2018 Oct; 233(10):6440-6454. PubMed ID: 29667769
[TBL] [Abstract][Full Text] [Related]
89. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
[TBL] [Abstract][Full Text] [Related]
90. The expression of inhibitor of bruton's tyrosine kinase gene is progressively up regulated in the clinical course of chronic lymphocytic leukaemia conferring resistance to apoptosis.
Albano F; Chiurazzi F; Mimmi S; Vecchio E; Pastore A; Cimmino C; Frieri C; Iaccino E; Pisano A; Golino G; Fiume G; Mallardo M; Scala G; Quinto I
Cell Death Dis; 2018 Jan; 9(1):13. PubMed ID: 29317636
[TBL] [Abstract][Full Text] [Related]
91. IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study.
Li Y; Buijs-Gladdines JG; Canté-Barrett K; Stubbs AP; Vroegindeweij EM; Smits WK; van Marion R; Dinjens WN; Horstmann M; Kuiper RP; Buijsman RC; Zaman GJ; van der Spek PJ; Pieters R; Meijerink JP
PLoS Med; 2016 Dec; 13(12):e1002200. PubMed ID: 27997540
[TBL] [Abstract][Full Text] [Related]
92. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
[TBL] [Abstract][Full Text] [Related]
93. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
[TBL] [Abstract][Full Text] [Related]
94. Glucocorticoid resistance and the AP-1 transcription factor in leukaemia.
Bailey S; Hall AG; Pearson AD; Reid MM; Redfern CP
Adv Exp Med Biol; 1999; 457():615-9. PubMed ID: 10500841
[TBL] [Abstract][Full Text] [Related]
95. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
Geethakumari PR; Awan F
Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
[TBL] [Abstract][Full Text] [Related]
96. The Role of MicroRNA in Paediatric Acute Lymphoblastic Leukaemia: Challenges for Diagnosis and Therapy.
Grobbelaar C; Ford AM
J Oncol; 2019; 2019():8941471. PubMed ID: 31737072
[TBL] [Abstract][Full Text] [Related]
97. MicroRNAs and the Diagnosis of Childhood Acute Lymphoblastic Leukemia: Systematic Review, Meta-Analysis and Re-Analysis with Novel Small RNA-Seq Tools.
Kyriakidis I; Kyriakidis K; Tsezou A
Cancers (Basel); 2022 Aug; 14(16):. PubMed ID: 36010971
[TBL] [Abstract][Full Text] [Related]
98. MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.
Ali A; Mahla SB; Reza V; Hossein A; Bahareh K; Mohammad H; Fatemeh S; Mostafa AB; Leili R
EJHaem; 2024 Feb; 5(1):191-205. PubMed ID: 38406506
[TBL] [Abstract][Full Text] [Related]
99. A Review of Acute Lymphocytic Leukemia (ALL) in the Pediatric Population: Evaluating Current Trends and Changes in Guidelines in the Past Decade.
Ekpa QL; Akahara PC; Anderson AM; Adekoya OO; Ajayi OO; Alabi PO; Okobi OE; Jaiyeola O; Ekanem MS
Cureus; 2023 Dec; 15(12):e49930. PubMed ID: 38179374
[TBL] [Abstract][Full Text] [Related]
100. Role of MicroRNAs in Cancer Development and Treatment.
Mehterov N
Int J Mol Sci; 2023 Jul; 24(13):. PubMed ID: 37446236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
